Adaptive Biotechnologies Corporation has announced a new partnership with Flatiron Health. The collaboration involves integrating Adaptive's clonoSEQ® test for measurable residual disease $(MRD.AU)$ assessment in lymphoid malignancies into Flatiron's cloud-based Electronic Medical Record $(EMR)$ platform, OncoEMR®. This integration aims to streamline access to vital MRD data, enabling over 4,500 clinicians at 1,000 community-based cancer care locations across the U.S. to order and review clonoSEQ MRD testing results directly within the EMR. The partnership is intended to enhance the efficiency of testing workflows and provide real-time insights into patients' disease status, thereby empowering community oncology practices to make more informed and personalized treatment decisions.